Early Economic Model of Extracorporeal Photopheresis and Other Treatments of Chronic Lung Allograft Dysfunction After Lung Transplantation

Summary

The authors built a Markov model with FEV1 percent states to explore the potential cost-effectiveness of treatments for confirmed CLAD, focusing on extracorporeal photopheresis (ECP). Base case incremental cost-effectiveness ratios for ECP ranged from 33,343 to 88,278 pounds per QALY, lower in BOS than RAS and in earlier CLAD stages. The abstract states that there was very little quality evidence to inform the model, results included a wide range, and key determinants were the benefit after stopping treatment, response under standard care and CLAD stage mortality. The model is to be updated as ongoing trials report.

Details

doi

10.36469/001c.163450

pmid

42798973

authors

Rice S, Coughlan D, Vale L, Cohen C, Benden C, Bennett D, Greer M, Parmar J, Tissot A, Vos R, Perez MA, Carby M, Thompson R, Santhanakrishnan K, Fisher AJ

journal

Journal of Health Economics and Outcomes Research

year

2026

volume

13

issue

2

Sources and links

• Publisher record via DOI (primary)
• PubMed 42798973

Related

Links from this record

• models: Extracorporeal photopheresis (ECP)
• authors affiliated with: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
• coauthor: Robin Vos

Linked from (derived)

• author affiliation matches this institution (OpenAlex): Nantes Thoracic Transplantation Unit (CHU de Nantes and institut du thorax)
• author affiliation matches this institution (OpenAlex): Newcastle Lung Transplant Programme (Freeman Hospital and Newcastle University)
• author: Robin Vos
• evidence: No therapy of proven benefit for established CLAD

Known gaps in this record

• full text not read (abstract only)
• funding statement and grant numbers
• full text and model inputs (not read)
• funding and conflicts of interest